Evidence map›Paper›PMID 29554887›Full record

SynthesisBMC cancer2018

CircRNAs as biomarkers of cancer: a meta-analysis.

Miao Wang, Yuxi Yang, Jian Xu, Wen Bai, Xueli Ren, Huijian Wu

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 12 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 12 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. The Emerging Role of Circular RNAs in Prostate Cancer: A Systematic Review.Frontiers in cell and developmental biology · 2021
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Miao WangSchool of Life Science and Biotechnology, Dalian University of Technology, No.2 Linggong Road, Dalian, Liaoning Province, 116024, China.
Yuxi YangSchool of Life Science and Biotechnology, Dalian University of Technology, No.2 Linggong Road, Dalian, Liaoning Province, 116024, China.
Jian XuPhysical Education Department, Dalian University of Technology, No.2 Linggong Road, Dalian, Liaoning Province, 116024, China.
Wen BaiPhysical Education Department, Dalian University of Technology, No.2 Linggong Road, Dalian, Liaoning Province, 116024, China.
Xueli RenSchool of Life Science and Biotechnology, Dalian University of Technology, No.2 Linggong Road, Dalian, Liaoning Province, 116024, China.
Huijian WuSchool of Life Science and Biotechnology, Dalian University of Technology, No.2 Linggong Road, Dalian, Liaoning Province, 116024, China. wuhj@dlut.edu.cn.

Funding

National Natural Science Foundation of China 81301504National Natural Science Foundation of China 81672792
6 · The paper itself

Abstract

backgroundThe expression of circular RNA (circRNA) may affect tumor progression. However, there have been no systemic meta-analysis for cancer diagnosis by using circRNAs in clinical till now. Herein, we aimed to collect and examined all the evidence on the potential role of circRNA as novel biomarker in human cancers.

methodsA comprehensive search strategy was used to search relevant literatures in the databases of PubMed, Embase, and the Web of Science from 2015 to August 2017. The correlation between circRNA expression and the diagnostic accuracy of tumor markers was analyzed. The methodological quality of each study was assessed by quality assessment for the diagnostic accuracies of the eligible studies (QUADAS-2). Statistical analysis was performed by applying the STATA (version 12.0) software.

resultsThe present meta-analysis included 1752 patients with circRNA expression data of tumor and paired adjacent non-tumorous tissues from 17 publications (19 studies). The pooled sensitivity, specificity, positive likelihood ratios (PLR), negative likelihood ratios (NLR), and diagnostic OR (DOR) with their 95% confidential intervals (95%CIs), and AUC values were 0.72 (0.67-0.76), 0.74 (0.69-0.78), 2.80 (2.40-3.10), 0.38 (0.33-0.44), 7.00 (6.00-9.00), and 0.79, respectively. Subgroup analyses showed that the expression of circRNA in tissues of hepatocellular carcinoma (HCC) group was more prone to be detected than other tumor types, with a high values of the specificity, DOR, and AUC.

conclusionscircRNAs might be suitable as diagnostic biomarkers for tumors, especially in HCC diagnosis. Further prospective studies on the diagnostic value of circRNAs from the different tumors are needed in the future.

Indexed as

SoftwareBiomarkers, TumorCarcinoma, HepatocellularHumansLiver NeoplasmsRNARNA, CircularBiomarkers, TumorRNARNA, CircularBiomarkerCancerCircRNA

Identifiers

PMID29554887
PMCPMC5859638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.